- Home
- BTX vs RLAY Comparison
BTX vs RLAY Comparison
Compare BTX & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTX | RLAY |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 773.8M | 1.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BTX | RLAY |
|---|---|---|
| Price | $6.61 | $8.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 930.0K | ★ 2.1M |
| Earning Date | 11-01-2025 | 11-06-2025 |
| Dividend Yield | ★ 13.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,355,000.00 |
| Revenue This Year | N/A | $20.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.10 | $1.78 |
| 52 Week High | $8.31 | $8.70 |
Technical Indicators
Market Signals| Indicator | BTX | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 43.76 | 63.19 |
| Support Level | $6.66 | $7.42 |
| Resistance Level | $6.84 | $8.00 |
| Average True Range (ATR) | 0.12 | 0.52 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 48.58 | 65.26 |
Price Performance
Historical ComparisonAbout BTX BlackRock Technology and Private Equity Term Trust
BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).